Abstract: AIM: To explore the effects of urate-lowering drugs (allopurinol and benzbromarone) on the heart function of chronic heart failure (CHF) patients complicated with hyperuricemia. METHODS: Sixty chronic heart failure patients complicated with hyperuricemia were selected and randomly divided into three groups. The control group was treated with conventional therapy, allopurinol group was treated with conventional therapy plus allopurinol and benzbromarone group was treated with conventional therapy plus benzbromarone. The changes of serum uric acid, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDD) and left ventricular end-systolic volume (LVESD) before and after treatment were compared 6 months after treatment. RESULTS: Both allopurinol and benzbromarone were effective in lowering uric acid. Compared with that in control group, significantly improved heart function of CHF patients was observed in allopurinol group (P<0.05), whereas no significant difference was found between control group and benzbromarone group. CONCLUSION: Allopurinol is superior in improving cardiac function of CHF patients by inhibition of xanthine oxidase compared with benzbromarone by elimination of uric acid.